Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
Mayo Clinic
Mayo Clinic
Hoffmann-La Roche
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Essen Biotech
National Institutes of Health Clinical Center (CC)
TCRCure Biopharma Ltd.
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
University Health Network, Toronto
Hadassah Medical Organization
University Health Network, Toronto
UNC Lineberger Comprehensive Cancer Center
TCR2 Therapeutics
TCR2 Therapeutics
Herlev Hospital
City of Hope Medical Center
M.D. Anderson Cancer Center
University of Southern California
Roswell Park Cancer Institute
Peking University
Immatics US, Inc.
Vall d'Hebron Institute of Oncology
Acepodia Biotech, Inc.
M.D. Anderson Cancer Center
University Health Network, Toronto
Mayo Clinic
SCG Cell Therapy Pte. Ltd.
National Institutes of Health Clinical Center (CC)
BioEclipse Therapeutics
HRYZ Biotech Co.
Gilead Sciences
Dana-Farber Cancer Institute
Leap Therapeutics, Inc.
Fate Therapeutics
Fate Therapeutics
Memorial Sloan Kettering Cancer Center
Fate Therapeutics
City of Hope Medical Center
Herlev Hospital
Barretos Cancer Hospital
Ludwig Institute for Cancer Research
Fudan University
Corregene Biotechnology Co., Ltd